Cryolife (NYSE:CRY) was downgraded by equities researchers at ValuEngine from a “strong-buy” rating to a “buy” rating in a report released on Wednesday, ValuEngine reports.

A number of other research firms have also recently weighed in on CRY. Needham & Company LLC reaffirmed a “hold” rating on shares of Cryolife in a research report on Wednesday, May 1st. TheStreet raised Cryolife from a “c” rating to a “b-” rating in a research report on Wednesday, May 1st. Canaccord Genuity reaffirmed a “buy” rating and set a $35.00 price objective (up from $32.00) on shares of Cryolife in a research report on Wednesday, May 1st. Zacks Investment Research cut Cryolife from a “hold” rating to a “sell” rating in a research report on Wednesday, February 20th. Finally, Northland Securities reaffirmed a “buy” rating and set a $32.00 price objective on shares of Cryolife in a research report on Thursday, January 17th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $31.91.

Shares of Cryolife stock traded up $0.10 during trading hours on Wednesday, reaching $30.02. 111,417 shares of the stock traded hands, compared to its average volume of 201,632. The company has a market cap of $1.12 billion, a P/E ratio of 115.46 and a beta of 0.54. Cryolife has a one year low of $23.99 and a one year high of $36.05. The company has a quick ratio of 3.69, a current ratio of 4.90 and a debt-to-equity ratio of 0.86.

Cryolife (NYSE:CRY) last released its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.04. The business had revenue of $67.50 million during the quarter, compared to the consensus estimate of $66.37 million. Cryolife had a positive return on equity of 3.79% and a negative net margin of 0.09%. The business’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.02 EPS. Research analysts anticipate that Cryolife will post 0.31 EPS for the current fiscal year.

In other news, CEO James P. Mackin sold 50,000 shares of Cryolife stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $31.31, for a total transaction of $1,565,500.00. Following the transaction, the chief executive officer now directly owns 220,731 shares of the company’s stock, valued at approximately $6,911,087.61. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Amy Horton sold 6,666 shares of Cryolife stock in a transaction dated Wednesday, March 6th. The shares were sold at an average price of $29.15, for a total value of $194,313.90. Following the transaction, the vice president now directly owns 103,713 shares in the company, valued at $3,023,233.95. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 106,775 shares of company stock worth $3,325,151. Insiders own 4.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Mason Street Advisors LLC lifted its holdings in Cryolife by 3.6% in the 1st quarter. Mason Street Advisors LLC now owns 10,938 shares of the medical equipment provider’s stock worth $319,000 after purchasing an additional 376 shares in the last quarter. Piedmont Investment Advisors Inc. lifted its holdings in Cryolife by 5.9% in the 1st quarter. Piedmont Investment Advisors Inc. now owns 8,602 shares of the medical equipment provider’s stock worth $251,000 after purchasing an additional 481 shares in the last quarter. US Bancorp DE lifted its holdings in Cryolife by 25.8% in the 1st quarter. US Bancorp DE now owns 2,540 shares of the medical equipment provider’s stock worth $74,000 after purchasing an additional 521 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in Cryolife by 2.2% in the 4th quarter. Thrivent Financial for Lutherans now owns 24,190 shares of the medical equipment provider’s stock worth $687,000 after purchasing an additional 532 shares in the last quarter. Finally, Legal & General Group Plc lifted its holdings in Cryolife by 0.8% in the 4th quarter. Legal & General Group Plc now owns 73,074 shares of the medical equipment provider’s stock worth $2,066,000 after purchasing an additional 588 shares in the last quarter. 71.23% of the stock is currently owned by institutional investors.

Cryolife Company Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

See Also: Price to Earnings Ratio (PE)

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cryolife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife and related companies with MarketBeat.com's FREE daily email newsletter.